Lexicon Pharmaceuticals Inc Quick Ratio (LXRX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lexicon Pharmaceuticals Inc   (NASDAQ: LXRX)

Lexicon Pharmaceuticals Inc 's Quick Ratio

LXRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 12.96 above Lexicon Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Quick Ratio than Lexicon Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 227 to 313.

Explain Quick Ratio?
How much Cash & cash equivalents LXRX´s has?
What are LXRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LXRX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -57.79 % -84.93 % -53.88 % -51.68 % 24.97 %
Y / Y Cash & cash equivalent Change 37.12 % -12.41 % -59.56 % -55.12 % -55.15 %
Quick Ratio MRQ 12.96 17.24 4.61 6.66 3.99
LXRX's Total Ranking # 313 # 227 # 349 # 296 #
Seq. Current Liabilities Change 48.58 % -52.57 % 19.81 % -50 % -46.97 %
Seq. Cash & cash equivalent Change 11.69 % 77.34 % -17.01 % -16.59 % -28.66 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 86
Healthcare Sector # 125
Overall Market # 313


Quick Ratio Statistics
High Average Low
19.59 6.14 1.31
(Dec 31 2010)   (Sep 30 2014)




Financial Statements
Lexicon Pharmaceuticals Inc 's Current Liabilities $ 15 Millions Visit LXRX's Balance sheet
Lexicon Pharmaceuticals Inc 's Cash & cash equivalent $ 191 Millions Visit LXRX's Balance sheet
Source of LXRX's Sales Visit LXRX's Sales by Geography


Cumulative Lexicon Pharmaceuticals Inc 's Quick Ratio

LXRX's Quick Ratio for the trailling 12 Months

LXRX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -65.41 % -52.52 % 4.71 % 37.29 % 57.99 %
Y / Y Cash & cash equivalent TTM Growth -30.92 % -47.87 % -53.01 % -37.13 % -21.24 %
Quick Ratio TTM 9.12 6.29 3.93 4.21 4.57
Total Ranking TTM # 3492 # 3569 # 2388 # 1959 #
Seq. Current Liabilities TTM Growth -24.25 % -40.19 % -14.94 % -10.25 % 3.98 %
Seq. Cash & cash equivalent TTM Growth 9.89 % -4.43 % -20.61 % -17.16 % -17.08 %

Quick ratio ranking by company, industry and sector >> Back to LXRX Financial Strength Comparisons >> Go to Compare LXRX Quick Ratio to its Competitors

On the trailing twelve months basis LXRX Cash & cash equivalent grew by 37.12 % in Q2 2026 year on year, while Current Liabilities soared to $15 millions, this led to increase in in Lexicon Pharmaceuticals Inc 's Quick Ratio to 9.12, above LXRX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 420 other companies have achieved higher Quick Ratio than Lexicon Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 3492, from total ranking during the twelve months ending first quarter 2026 at 3569.

Explain Quick Ratio?
How much Cash & cash equivalents LXRX´s has?
What are LXRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 421
Healthcare Sector # 856
Within the Market # 3492


trailing twelve months Quick Ratio Statistics
High Average Low
11.74 5.15 1.84
(Sep 30 2012)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Mineralys Therapeutics Inc   34.87 $ 673.704  Millions$ 19.319  Millions
Praxis Precision Medicines Inc   34.32 $ 1,683.790  Millions$ 49.058  Millions
Agios Pharmaceuticals Inc   33.94 $ 2,383.112  Millions$ 70.217  Millions
Mbx Biosciences Inc   33.10 $ 783.099  Millions$ 23.660  Millions
Xbiotech Inc   32.67 $ 109.528  Millions$ 3.353  Millions
Avalo Therapeutics Inc   31.89 $ 787.143  Millions$ 24.682  Millions
Fulcrum Therapeutics Inc   30.96 $ 318.840  Millions$ 10.298  Millions
Climb Bio Inc   30.86 $ 183.123  Millions$ 5.934  Millions
Indaptus Therapeutics Inc   29.61 $ 15.554  Millions$ 0.525  Millions
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions
Rallybio Corporation  26.02 $ 92.800  Millions$ 3.567  Millions
Assembly Biosciences Inc   25.95 $ 608.475  Millions$ 23.445  Millions
Arbutus Biopharma Corp  25.84 $ 92.625  Millions$ 3.585  Millions
Immix Biopharma Inc   25.49 $ 238.715  Millions$ 9.364  Millions
Boundless Bio Inc   25.00 $ 194.230  Millions$ 7.768  Millions
Sionna Therapeutics Inc   24.88 $ 268.300  Millions$ 10.782  Millions
Prothena Corporation Public Limited Company  24.72 $ 288.193  Millions$ 11.658  Millions
Zenas Biopharma Inc   24.28 $ 1,597.761  Millions$ 65.818  Millions
Neuphoria Therapeutics Inc   23.89 $ 19.866  Millions$ 0.832  Millions
Innoviva Inc   23.77 $ 1,118.871  Millions$ 47.064  Millions
Pepgen Inc   23.51 $ 211.674  Millions$ 9.005  Millions

Date modified: 2026-09-08T13:54:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.